9/23/2022 7:02:30 AM
Bausch Health And Glenmark Announce Approval Of RYALTRIS In Canada
9/9/2022 7:03:31 AM
Bausch Health Responds To Norwich Pharma Tentative FDA Approval For 200 Mg Rifaximin
8/22/2022 7:08:46 AM
Bausch Health Transfers Common Shares Equal To About 38.6% Shares Of Bausch + Lomb
8/9/2022 7:14:26 AM
Bausch Health Now Sees FY Revenue Of $8.05 Bln To $8.22 Bln Vs. Prior View Of $8.25 Bln To $8.40 Bln
8/9/2022 7:10:40 AM
Bausch Health Q2 Loss Per Share $0.40 Vs Loss $1.66 Last Year
7/20/2022 7:09:46 AM
Bausch + Lomb : Joseph Papa Stepped Down As Chair Of Board Of Directors
5/10/2022 12:58:56 PM
Bausch Health And Bausch + Lomb Announce Closing Of IPO Of Bausch + Lomb And Related Debt Transactions
5/10/2022 7:18:19 AM
Bausch Health Q1 Total Reported Revenues $1.918 Bln, Decrease Of 5% From Prior Year
5/6/2022 12:20:50 PM
Bausch Health Appoints Thomas Appio As CEO
5/5/2022 8:50:12 PM
Bausch + Lomb Announces Pricing Of IPO Of 35.00 Mln Common Shares At $18.00/shr
4/28/2022 9:57:17 AM
Bausch + Lomb Announces Launch Of IPO And Roadshow
4/25/2022 7:00:41 AM
Bausch + Lomb Presents Data From First Phase 3 Trial Of Investigational Treatment NOV03 At ASCRS Annual Meeting
4/21/2022 7:00:44 AM
Bausch + Lomb Reports More Than 48 Mln Units Of Contact Lens, Eye Care And Lens Care Materials Recycled
4/20/2022 7:02:35 AM
Bausch + Lomb Seeks To Enter Into New Credit Facilities To Facilitate Separation From Bausch Health
3/28/2022 7:00:14 AM
Bausch + Lomb And Clearside Biomedical Announce The U.S. Commercial Launch Of XIPERE